U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H27N3O2
Molecular Weight 269.3831
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRAMIRACETAM

SMILES

CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C

InChI

InChIKey=ZULJGOSFKWFVRX-UHFFFAOYSA-N
InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)

HIDE SMILES / InChI

Description

Scientists at Parke-Davis first synthesized Pramiracetam (brand name Pramistar) in the late 1970’s. It was first tested with Alzheimer’s patients. Seeing mixed results, the company tried it with major depressive disorder and licensed it as an orphan drug to Menarini. Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. Pramistar is used for the treatment of concentration and memory disturbances caused by the degeneration of brain cells or to diseases of the blood vessels supplying the brain, conditions that arise both in elderly patients (aged over 65 years). By stimulating choline uptake, pramiracetam indirectly modulates the release of acetylcholine and stimulates increased activity in the hippocampus. Because this part of the brain is absolutely crucial to the memory function, the general stimulation that pramiracetam creates can improve both the formation of new memories and the retention of reference or long-term memories. The increased activity in the hippocampus also increases cerebral blood flow, which enhances alertness and improves cognitive abilities in general. Pramiracetam may have other mechanisms of action as well. Researchers have hypothesized that in addition to its action in the brain, pramiracetam acts outside the brain in peripheral sites that rely on the adrenal glands. Animal studies suggest that pramiracetam may also increase or restore brain membrane fluidity, which facilitates cell signaling. Unlike many other racetam class nootropics, pramiracetam does not appear to strongly alter either wakefulness or emotional states. This can be explained by pramiracetam’s very limited influence on the production and release of serotonin, GABA and dopamine, the neurotransmitters that have the greatest effect on mood and anxiety levels.

CNS Activity

Originator

Target Info

Target Info

Primary TargetPharmacologyConditionPotency
Condition Info

Condition Info

ConditionModalityTargetsHighest PhaseProduct
Palliative
PRAMISTAR
PMID

PMID

TitleDatePMID
Therapeutic approaches to age-associated neurocognitive disorders.
2001 Sep
[Experience in the application of pramistar, a new nootropic preparation, in the treatment of memory disorders in patients with cerebrovascular pathology].
2003 Dec
Brahmi rasayana improves learning and memory in mice.
2006 Mar
[Application of nootropic agents in complex treatment of patients with concussion of the brain].
2007 Jul-Sep
Diisoprop-yl{2-[2-(2-oxopyrrolidin-1-yl)acetamido]eth-yl}ammonium hydrogen sulfate.
2008 May 30
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
2010 Feb 12
Patent

Patent

Sample Use Guides

In Vivo Use Guide
is one tablet of 600 mg twice a day, morning and evening. Swallow the tablets with a drink of water. Do not exceed the daily dose of 1,200 mg.
Route of Administration: Oral
Name Type Language
PRAMIRACETAM
INN   MI   WHO-DD  
INN  
Official Name English
N-(2-(DIISOPROPYLAMINO)ETHYL)-2-OXO-1-PYRROLIDINEACETAMIDE
Systematic Name English
PRAMIRACETAM [INN]
Common Name English
PRAMIRACETAM [MI]
Common Name English
1-PYRROLIDINEACETAMIDE, N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-OXO-
Systematic Name English
PRAMIRACETAM [WHO-DD]
Common Name English
CI-879 FREE BASE
Code English
Classification Tree Code System Code
WHO-ATC N06BX16
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
WHO-VATC QN06BX16
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
Code System Code Type Description
MESH
C038438
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
EPA CompTox
68497-62-1
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
INN
5054
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
EVMPD
SUB09991MIG
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
CAS
68497-62-1
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
WIKIPEDIA
PRAMIRACETAM
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
NCI_THESAURUS
C84171
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
MERCK INDEX
M9096
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY Merck Index
ChEMBL
CHEMBL159776
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY
PUBCHEM
51712
Created by admin on Tue Mar 06 12:04:01 UTC 2018 , Edited by admin on Tue Mar 06 12:04:01 UTC 2018
PRIMARY SWITZERF